Proinflammatory cytokines, immune response and tumour progression

Novartis Foundation Symposium

Volumn 256, Issue , 2004, Pages 92-99

  Spadaro, Michela ^a   Forni, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL; CELLULAR IMMUNITY; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; NEOPLASMS;

EID: 2142766684     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (23)

1. Allione A, Consalvo M, Nanni P et al 1994 Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022-6026
2. Balkwill F, Mantovani A 2001 Inflammation and cancer: back to Virchow? Lancet 357:539-545
3. Boggio K, Nicoletti G, Di CarloEet al 1998 Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589-596
4. Cavallo F, Signorelli P, Giovarelli M et al 1997 Antitumour efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049-1058
5. Cavallo F, Di Carlo E, Quaglino E et al 2001 Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. J Biol Regul Homeost Agents 15:351-358
6. Cifaldi L, Quaglino E, Di Carlo E et al 2001 A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 61:2809-2812
7. Colombo MP, Modesti A, Parmiani G, Forni G 1992 Local cytokine availability elicits tumour rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52:4853-4857
8. Cortesina G, De Stefani A, Giovarelli M et al 1988 Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482-2485
9. Cortesina G, De Stefani A, Galeazzi E et al 1991 Interleukin-2 injected around tumour-draining lymph nodes in head and neck cancer. Head Neck 13:125-131
10. Cortesina G, De Stefani A, Galeazzi E et al 1994 Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 69:572-576
11. De Stefani A, Forni G, Ragona R et al 2002 Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95:90-97
12. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P 2001 The intriguing role of polymorphonuclear neutrophils in antitumour reactions. Blood 97:339-345
13. Forni G, Giovarelli M, SantoniA1985 Lymphokine-activated tumour inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumour-bearing mice to inhibit tumour growth. J Immunol 134(2):1305-1311
14. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M 1987 Interleukin 2 activated tumour inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 138:4033-4041
15. Forni G, Giovarelli M, Cavallo F et al 1993 Cytokine induced tumour immunogenicity: from exogenous cytokines to gene therapy. J Immunother 14:253-257
16. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L 1992 The origin and function of tumour-associated macrophages. Immunol Today 13:265-270
17. Mihm MC Jr, Clemente CG, Cascinelli N 1996 Tumour infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47
18. Musiani P, De Campora E, Valitutti S et al 1989 Effect of low doses of interleukin-2 injected perilymphatically and peritumourally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Response Mod 8:571-578
19. Musiani P, Modesti A, Giovarelli M et al 1997 Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18:32-36
20. Noguchi Y, Jungbluth A, Richards EC, Old LJ 1998. Effect of interleukin 12 on tumour induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 93:11798-11801
21. Pekarek LA, Weichselbaum RR, Beckett MA, Nachman J, Schreiber H 1993 Footprinting of individual tumours and their variants by constitutive cytokine expression patterns. Cancer Res 53:1978-1981
22. Pekarek LA, Starr BA, Toledano AY, Schreiber H 1995 Inhibition of tumour growth by elimination of granulocytes. J Exp Med 181:435-440
23. Strasly M, Cavallo F, Geuna M et al 2001 IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166:3890-3899